Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
候选生物类似药 CT-P43 与原研药 Ustekinumab 治疗中重度斑块状银屑病的疗效和安全性:一项随机、活性对照、双盲 III 期研究的 28 周结果
期刊:BioDrugs
影响因子:6.9
doi:10.1007/s40259-023-00630-5
Papp, Kim A; Lebwohl, Mark G; Thaçi, Diamant; Jaworski, Janusz; Kwiek, Bartlomiej; Trefler, Jakub; Dudek, Anna; Szepietowski, Jacek C; Reznichenko, Nataliya; Narbutt, Joanna; Baran, Wojciech; Kolinek, Joanna; Daniluk, Stefan; Bartnicka-Maslowska, Katarzyna; Reich, Adam; Andrashko, Yuriy; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Jung, Jinsun; Lee, Hyunseung; Pyo, Tina; Ko, Woori